Medikamentöse Therapie der ADHS bei Erwachsenen

Michael Rösler; Wolfgang Retz

doi:10.1055/a-0891-1940

PSYCH up2date, Inhaltsverzeichnis

PSYCH up2date 2020; 14(01): 59-75
DOI: 10.1055/a-0891-1940

Persönlichkeitsstörungen, Impulskontrollstörungen und dissoziative Störungen

Medikamentöse Therapie der ADHS bei Erwachsenen

Michael Rösler

,

Wolfgang Retz

Verantwortlicher Herausgeber dieser Rubrik: Wissenschaftlich verantwortlich gemäß Zertifizierungsbestimmungen für diesen Beitrag ist Prof. Dr. med. Michael Rösler, Homburg/Saar.

Abstract

Alle Artikel dieser Rubrik

Die pharmakologische Behandlung der Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (ADHS) ist bei Kindern, Jugendlichen und Erwachsenen der zentrale Baustein eines therapeutischen Gesamtkonzeptes, in dem auch psychosoziale Interventionen mit Psychoedukation oder spezifische psychotherapeutischen Maßnahmen, wie die kognitive Verhaltenstherapie, ihren Platz haben.

Schlüsselwörter

ADHS - Erwachsene - Pharmakotherapie - Stimulanzien

Volltext

Referenzen

Literatur
1 Rösler M, Retz W. Die Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (ADHS) im Erwachsenenalter. Z Psychiatrie Psychol Psychother 2006; 54: 77-86
2 Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften. S3-Leitlinie: ADHS im Kindes-, Jugend- und Erwachsenenalter. Registernummer 028-045. AWMF; 2017
3 de Zwaan M, Gruß B, Müller A. et al. The estimated prevalence and correlates of adult ADHD in a German community sample. Eur Arch Psychiatry Clin Neurosci 2011; 262: 79-86
4 Michielsen M, Semeijn E, Comijs HC. et al. Prevalence of attention-deficit hyperactivity disorder in older adults in The Netherlands. Brit J Psychiat 2012; 201: 298-305
5 Bradley C. The behavior of children receiving Benzedrine. Am J Psychiatry 1937; 94: 577-585
6 Bachmann J, Philipsen A, Hoffmann F. ADHS in Deutschland: Trends in Diagnose und medikamentöser Therapie. Deutsches Ärzteblatt 2017; 114: 141-148
7 Retz W, Rösler M. Therapieresistenz in der Behandlung von ADHS im Erwachsenenalter. In: Schmaus M, Messer T. Therapieresistenz bei psychischen Erkrankungen. München: Elsevier; 2009: 175-188
8 Faraone SV, Spencer T, Aleardi M. et al. Meta-analysis of the efficacy of methylphenidate for treating adult attention‐deficit/hyperactivity disorder. J Clin Psychopharmacol 2004; 24: 24-29
9 Koesters M, Becker T, Kilian R. et al. Limits of meta-analysis: Methylphenidate in the treatment of adult attention‐deficit hyperactivity disorder. J Psychopharmacol 2009; 23: 733-744
10 Castells X, Ramos-Quiroga JA, Rigau D. et al. Efficacy of methylphenidate for adults with attention‐deficit hyperactivity disorder: a meta‐regression analysis. CNS Drugs 2011; 25: 157-169
11 Mészáros A, Czobor P, Bálint S. et al. Pharmacotherapy of adult attention deficit hyperactivity disorder (ADHD): a meta‐analysis. Int J Neuropsychopharmacol 2009; 12: 1137-1147
12 Faraone SV, Glatt SJ. A comparison of the efficacy of medications for adult attention‐deficit/hyperactivity disorder using meta‐analysis of effect sizes. J Clin Psychiatry 2010; 71: 754-763
13 Cunill R, Castells X, Tobias A. et al. Efficacy, safety and variability in pharmacotherapy for adults with attention deficit hyperactivity disorder: a meta‐analysis and meta‐regression in over 9000 patients. Psychopharmacol 2016; 233: 187-197
14 Stuhec M, Lukić P, Locatelli I. Efficacy, acceptability, and tolerability of lisdexamfetamine, mixed amphetamine salts, methylphenidate, and modafinil order in adults: a systematic review and meta-analysis. Ann Pharmacother 2018; 53: 121-133
15 Cortese S, Adamo N, Del Giovane C. et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry 2018; 5: 727-738
16 Castells X, Blanco-Silvente L, Cunill R. Amfetamines for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database Syst Rev 2018; 9: CD007813
17 Retz W, Stieglitz RD, Corbisiero S. et al. Emotional dysregulation in adult ADHD: what is the empirical evidence?. Exp Rev Neurother 2012; 12: 1241-1251
18 Rösler M, Retz W, Fischer R. et al. Twenty-four-week treatment with extended release methylphenidate improves emotional symptoms in adult ADHD. World J Biol Psychiatry 2010; 11: 709-718
19 Rösler M, Ginsberg Y, Arngrim T. et al. Correlation of symptomatic improvements with functional improvements and patient-reported outcomes in adults with attention-deficit/hyperactivity disorder treated with OROS methylphenidate. World J Biol Psychiatry 2011; 14: 282-290
20 Retz W, Rösler M, Ose C. et al. Multiscale assessment of treatment efficacy in adults with ADHD: A randomized placebo-controlled, multi-centre study with extended-release methylphenidate. World J Biol Psychiatry 2012; 13: 48-59
21 Adler LA, Dirks B, Deas P. et al. Self-Reported quality of life in adults with attention-deficit/hyperactivity disorder and executive function impairment treated with lisdexamfetamine dimesylate: A randomized, double-blind, multicenter, placebo-controlled, parallel-group study. BMC Psychiatry 2013; 13: 253
22 Huss M, Ginsberg Y, Tvedten T. et al. Methylphenidate hydrochloride modified-release in adults with attention deficit hyperactivity disorder: a randomized double-blind placebo-controlled trial. Adv Ther 2014; 31: 44-65
23 Man KK, Chan EW, Coghill D. et al. Methylphenidate and the risk of trauma. Pediatrics 2015; 135: 40-48
24 Man KK, Ip P, Chan EW. et al. Effectiveness of pharmacological treatment for attention-deficit/hyperactivity disorder on physical injuries: a systematic review and meta-analysis of observational studies. CNS Drugs 2017; 31: 1043-1055
25 Schermann H, Gurel R, Ankory R. et al. Lower risk of fractures under methylphenidat treatment for ADHD: a dose-response effect. J Orthop Res 2018; 36: 3328-3333
26 Daalsgard S, Ostergaard S, Leckman J. et al. Mortality in children, adolescents, and adults with attention deficit hyperactivity disorder: a nationwide cohort study. Lancet 2015; 385: 2190-2196
27 Chang Z, Quinn P, Hur K. et al. Association between medication use for attention-deficit/hyperactivity disorder and risk of motor vehicle crashes. JAMA Psychiatry 2017; 74: 597-603
28 Lichtenstein P, Halldner L, Zetterqvist J. et al. Medication for attention deficit-hyperactivity disorder and criminality. N Engl J Med 2012; 367: 2006-2014
29 Shaw M, Hodgkins P, Caci H. et al. A systematic review and analysis of long-term outcomes in attention deficit hyperactivity disorder: effects of treatment and non-treatment. BMC Med 2012; 10: 99
30 Sobanski E, Retz W, Fischer R. et al. Treatment adherence and persistence in adult ADHD: results from a twenty-four week controlled clinical trial with extended release methylphenidate. Eur Psychiatry 2014; 29: 324-330
31 Fredriksen M, Halmøy A, Faraone SV. et al. Longterm efficacy and safety of treatment with stimulants and atomoxetine in adult ADHD: A review of controlled and naturalistic studies. Eur Neuropsychopharmacol 2013; 23: 508-527
32 Retz W, Retz-Junginger P, Römer K. et al. Standardisierte Skalen zur strukturierten Diagnostik der ADHS im Erwachsenenalter. Fortschr Neurol Psychiatr 2013; 81: 381-389
33 Manor I, Rozen S, Zemishlani Z. et al. When does it end? Attention-deficit/hyperactivity disorder in the middle aged and older populations. Clin Neuropharmacol 2011; 34: 148-154
34 Sobanski E, Schredl M, Kettler N. et al. Sleep in adults with attention deficit hyper-activity disorder (ADHD) before and during treatment with methylphenidate: a controlled polysomnographic study. Sleep 2008; 31: 375-381
35 Coghill DR, Caballero B, Sorooshian S. et al. A systematic review of the safety of lisdexamfetamine dimesylate. CNS Drugs 2014; 28: 497-511
36 Habel LA, Cooper WO, Sox CM. et al. ADHD medications and risk of serious cardiovascular events in young and middle‐aged adults. JAMA 2011; 306: 2673-2683
37 Mick E, McManus DD, Goldberg RJ. Meta‐analysis of increased heart rate and blood pressure associated with CNS stimulant treatment of ADHD in adults. Eur Neuropsychopharmacol 2013; 23: 534-541
38 Huybrechts KF, Bröms G, Christensen LB. et al. Association between Methylphenidate and Amphetamine use in pregnancy and risk of congenital malformations: a cohort study from the International Pregnancy Safety Study Consortium. JAMA Psychiatry 2018; 75: 167-175
39 Wilens TE, Adler LA, Adams J. et al. Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J Am Acad Child Adolesc Psychiatry 2008; 47: 21-31
40 Benson K, Flory KHumphreys KL. et al. Misuse of stimulant medication among college students: a comprehensive review and meta-analysis. Clin Child Fam Psychol Rev 2015; 18: 50-76
41 Humphreys KL, Eng T, Lee SS. Stimulant medication and substance use outcomes: a meta-analysis. JAMA Psychiatry 2013; 70: 740-749
42 Chang Z, Lichtenstein P, Halldner L. et al. Stimulant ADHD medication and risk for substance abuse. J Child Psychol Psychiat 2014; 55: 878-885
43 Retz-Junginger P, Retz W, Blocher D. et al. Wender Utah Rating Scale (WURS-k): Die deutsche Kurzform zur retrospektiven Erfassung des hyperkinetischen Syndroms bei Erwachsenen. Nervenarzt 2002; 73: 830-838
44 Rösler M, Retz W, Retz-Junginger P. et al. Instrumente zur Diagnostik der Aufmerksamkeits-/Hyperaktivitätsstörung im Erwachsenenalter: Selbstbeurteilungsskala (ADHS-SB) und Diagnose Checkliste (ADHS-DC). Nervenarzt 2004; 75: 365-371
45 Cunill R, Castells X, Tobias A. et al. Atomoxetine for attention deficit hyperactivity disorder in the adulthood: A meta‐analysis and meta-regression. Pharmacoepidemiol Drug Saf 2013; 22: 961-969
46 Asherson P, Stes S, Nilsson MarkhedM. et al. The effects of atomoxetine on emotional control in adults with ADHD: an integrated analysis of multicenter studies. European Psychiatry 2015; 30: 511-520
47 Michelson D, Adler L, Spencer T. et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry 2003; 53: 112-120
48 Walker DJ, Mason O, Clemow DB. et al. Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder. Postgrad Med J 2015; 127: 686-701
49 Banaschewski T, Becker K, Döpfner M. et al. Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung. Deutsches Ärzteblatt 2017; 114: 149-159
50 Moukhtarian TR, Cooper RE, Vassos E. et al. Effects of stimulants and atomoxetine on emotional lability in adults: a systematic review and meta-analysis. Eur Psychiatry 2017; 44: 198-207
51 Rösler M, Retz-Junginger P, Retz W. et al. Homburger ADHS‐Skalen für Erwachsene (HASE). Göttingen: Hogrefe; 2008
52 Christiansen H, Hirsch O, Abdel-Hamid M. et al. CAARS – Conners Skalen zu Aufmerksamkeit und Verhalten für Erwachsene. Göttingen: Hogrefe; 2014
53 Schmidt S, Petermann F. ADHS-E – ADHS-Screening für Erwachsene. Frankfurt: Pearson; 2009
54 Lauth GW, Minsel WR. KATE – Kölner ADHS-Test für Erwachsene. Göttingen: Hogrefe; 2014
55 Retz-Junginger P, Giesen L, Philipp-Wiegmann F. et al. Der Wender‐Reimherr‐Selbstbeurteilungsfragebogen zur adulten ADHS. Nervenarzt 2017; 88: 797-801